Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Ayala Pharmaceuticals, Inc.ADXS · Entity 93434 | Chief Financial Officer | March 29, 2018 | April 03, 2018 |
| INSMED IncINSM · Entity 3174 | Chief Financial Officer | June 03, 2026 | June 05, 2026 |
| Latigo Biotherapeutics, Inc.LTGO · Entity 4709 | Director | August 06, 2026 | August 07, 2026 |
| ONCOSEC MEDICAL IncONCS · Entity 117092 | CFO/COO | January 16, 2020 | January 21, 2020 |
| Xilio Therapeutics, Inc.XLO · Entity 7122 | Director | June 11, 2026 | June 12, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Ayala Pharmaceuticals, Inc.
Report date March 29, 2018 · Filed April 03, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 226,670 |
Reported balance
After 2018-03-29 transaction · row 1
1 source rowRow 1 · 2018-03-29 · Grant · Acquired 1,088 · Balance 226,670 F1: The reporting voluntarily person purchases restricted stock directly from the Company at market price on the last trading day of the month pursuant to an arrangement that was approved by the Compensation Committee of the Company's Board of Directors in a manner that satisfied Exchange Act Rule 16b-3(d). The Company utilizes the net withholding method for each monthly purchase. The reporting person purchased a gross amount of 1,365 shares of which 277 shares were forfeited to pay withholding taxes associated with the stock issuance. |
Filing footnotes · ownership attribution and instrument terms
F1: The reporting voluntarily person purchases restricted stock directly from the Company at market price on the last trading day of the month pursuant to an arrangement that was approved by the Compensation Committee of the Company's Board of Directors in a manner that satisfied Exchange Act Rule 16b-3(d). The Company utilizes the net withholding method for each monthly purchase. The reporting person purchased a gross amount of 1,365 shares of which 277 shares were forfeited to pay withholding taxes associated with the stock issuance.
INSMED Inc
Report date June 03, 2026 · Filed June 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 69,082 |
Reported balance
After 2026-06-03 transaction · row 1
1 source rowRow 1 · 2026-06-03 · Sale · Disposed 2,404 · Balance 69,082 F1: Shares sold to satisfy tax withholding obligations upon the vesting of Restricted Stock Units and to cover related broker fees. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares sold to satisfy tax withholding obligations upon the vesting of Restricted Stock Units and to cover related broker fees.
Latigo Biotherapeutics, Inc.
Report date August 06, 2026 · Filed August 07, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.16 · Expires 2036-04-06 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-08-06 · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · Balance Not disclosed F1: The shares subject to this option shall vest in 48 equal monthly installments after April 1, 2026. The shares subject to this option are early exercisable, subject to the Issuer's right of repurchase. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to this option shall vest in 48 equal monthly installments after April 1, 2026. The shares subject to this option are early exercisable, subject to the Issuer's right of repurchase.
ONCOSEC MEDICAL Inc
Report date January 16, 2020 · Filed January 21, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 41,389 |
Reported balance
After 2020-01-16 transaction · row 1
1 source rowRow 1 · 2020-01-16 · Sale · Disposed 1,351 · Balance 41,389 F1: In connection with the vesting of 3,906 RSUs on January 16, 2020, a total of 1,351 shares were sold in order to satisfy the reporting person's tax withholding obligations. The reporting person had no discretion with respect to such withholding, which was conducted automatically in accordance with the issuer's corporate policies. |
Filing footnotes · ownership attribution and instrument terms
F1: In connection with the vesting of 3,906 RSUs on January 16, 2020, a total of 1,351 shares were sold in order to satisfy the reporting person's tax withholding obligations. The reporting person had no discretion with respect to such withholding, which was conducted automatically in accordance with the issuer's corporate policies.
Xilio Therapeutics, Inc.
Report date June 11, 2026 · Filed June 12, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.99 · Expires 2036-06-10 | Direct | 5,000 |
Reported balance
After 2026-06-11 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-11 · Grant · Acquired 5,000 · Balance 5,000 F1: The option was granted on June 11, 2026 and will vest as to 100% of the shares underlying the option on the earlier of (i) June 11, 2027 and (ii) the Issuer's next annual meeting of stockholders following the grant date, subject to the Reporting Person's continued service to the Issuer through the vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option was granted on June 11, 2026 and will vest as to 100% of the shares underlying the option on the earlier of (i) June 11, 2027 and (ii) the Issuer's next annual meeting of stockholders following the grant date, subject to the Reporting Person's continued service to the Issuer through the vesting date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
scPharmaceuticals Inc.
Report date October 07, 2025 · Filed October 07, 2025
Section 16 reporting ended · disclosed 2025-10-07. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.85 · Expires 2035-06-03 | Direct | 0 |
Reported balance
After 2025-10-07 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-10-07 · Disposition to issuer · Disposed 30,000 · Balance 0 F1: In connection with the terms of an Agreement and Plan of Merger, dated as of August 24, 2025 (the "Merger Agreement"), by and among the Issuer, MannKind Corporation ("Parent") and Seacoast Merger Sub, Inc., a direct wholly owned subsidiary of Parent ("Purchaser"), Purchaser completed a tender offer for shares of the Issuer's common stock ("Common Stock") on October 7, 2025. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (a "Company Option") that was outstanding and unexercised as of immediately prior to the Effective Time and that had an exercise price per share that was less than $5.35, whether or not then vested or exercisable, was cancelled and converted into the right to receive (i) an amount in cash, F2: (Continued from footnote 1) without interest and subject to any applicable withholding taxes, equal to (A) the total number of shares subject to such Company Option immediately prior to such cancellation multiplied by (B) the excess, if any, of (x) $5.35 over (y) the exercise price payable per share underlying such Company Option and (ii) one CVR in respect of each share subject to such Company Option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.11 · Expires 2034-06-11 | Direct | 0 |
Reported balance
After 2025-10-07 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2025-10-07 · Disposition to issuer · Disposed 19,750 · Balance 0 F1: In connection with the terms of an Agreement and Plan of Merger, dated as of August 24, 2025 (the "Merger Agreement"), by and among the Issuer, MannKind Corporation ("Parent") and Seacoast Merger Sub, Inc., a direct wholly owned subsidiary of Parent ("Purchaser"), Purchaser completed a tender offer for shares of the Issuer's common stock ("Common Stock") on October 7, 2025. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (a "Company Option") that was outstanding and unexercised as of immediately prior to the Effective Time and that had an exercise price per share that was less than $5.35, whether or not then vested or exercisable, was cancelled and converted into the right to receive (i) an amount in cash, F2: (Continued from footnote 1) without interest and subject to any applicable withholding taxes, equal to (A) the total number of shares subject to such Company Option immediately prior to such cancellation multiplied by (B) the excess, if any, of (x) $5.35 over (y) the exercise price payable per share underlying such Company Option and (ii) one CVR in respect of each share subject to such Company Option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.53 · Expires 2032-06-14 | Direct | 0 |
Reported balance
After 2025-10-07 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2025-10-07 · Disposition to issuer · Disposed 16,300 · Balance 0 F1: In connection with the terms of an Agreement and Plan of Merger, dated as of August 24, 2025 (the "Merger Agreement"), by and among the Issuer, MannKind Corporation ("Parent") and Seacoast Merger Sub, Inc., a direct wholly owned subsidiary of Parent ("Purchaser"), Purchaser completed a tender offer for shares of the Issuer's common stock ("Common Stock") on October 7, 2025. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (a "Company Option") that was outstanding and unexercised as of immediately prior to the Effective Time and that had an exercise price per share that was less than $5.35, whether or not then vested or exercisable, was cancelled and converted into the right to receive (i) an amount in cash, F2: (Continued from footnote 1) without interest and subject to any applicable withholding taxes, equal to (A) the total number of shares subject to such Company Option immediately prior to such cancellation multiplied by (B) the excess, if any, of (x) $5.35 over (y) the exercise price payable per share underlying such Company Option and (ii) one CVR in respect of each share subject to such Company Option. |
Filing footnotes · ownership attribution and instrument terms
F1: In connection with the terms of an Agreement and Plan of Merger, dated as of August 24, 2025 (the "Merger Agreement"), by and among the Issuer, MannKind Corporation ("Parent") and Seacoast Merger Sub, Inc., a direct wholly owned subsidiary of Parent ("Purchaser"), Purchaser completed a tender offer for shares of the Issuer's common stock ("Common Stock") on October 7, 2025. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (a "Company Option") that was outstanding and unexercised as of immediately prior to the Effective Time and that had an exercise price per share that was less than $5.35, whether or not then vested or exercisable, was cancelled and converted into the right to receive (i) an amount in cash,
F2: (Continued from footnote 1) without interest and subject to any applicable withholding taxes, equal to (A) the total number of shares subject to such Company Option immediately prior to such cancellation multiplied by (B) the excess, if any, of (x) $5.35 over (y) the exercise price payable per share underlying such Company Option and (ii) one CVR in respect of each share subject to such Company Option.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 03, 2025 Filed Jun 4, 2025 21:36 UTC | INSMED Inc INSM · Entity 3174 | SaleCommon Stock | 1,579 | $71.50 | $112,898.50 |
DisclosureSEC source: 0001628280-25-029405 · wk-form4_1749072980.xml · nonDerivative · entry 1 Bonstein Sara · CIK 0001604019 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 113,288 F1 · kind: Shares sold to satisfy tax withholding obligations upon the vesting of Restricted Stock Units and to cover related broker fees. Read SEC document |
| June 03, 2025 Filed Jun 5, 2025 16:49 UTC | scPharmaceuticals Inc. SCPH · Entity 74456 | GrantStock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $3.85 | $0.00 |
DisclosureSEC source: 0000950170-25-082436 · ownership.xml · derivative · entry 1 Bonstein Sara · CIK 0001604019 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2035-06-03 F1 · derivative.exercise_date: This stock option vests in full upon the earlier of (i) June 3, 2026, or (ii) the next annual meeting of the Issuer's stockholders. Read SEC document |
| May 15, 2025 Filed May 19, 2025 21:06 UTC | INSMED Inc INSM · Entity 3174 | GrantStock Option (right to buy) · Derivative | 31,610 | $0.00 Strike: $67.22 | $0.00 |
DisclosureSEC source: 0001628280-25-026586 · wk-form4_1747688783.xml · derivative · entry 2 Bonstein Sara · CIK 0001604019 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,610 Underlying: Common Stock · 31,610 shares Expires 2035-05-15 F3 · derivative.exercise_date: These stock options were granted under the Company's Amended and Restated 2019 Incentive Plan, as amended. The options become exercisable based on the following vesting schedule: 25% vest on the Initial Vesting Date and an additional 12.5% vest every six months thereafter until fully vested. Read SEC document |
| May 15, 2025 Filed May 19, 2025 21:06 UTC | INSMED Inc INSM · Entity 3174 | GrantCommon Stock | 6,508 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-25-026586 · wk-form4_1747688783.xml · nonDerivative · entry 1 Bonstein Sara · CIK 0001604019 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 114,867 F1 · shares: Represents Restricted Stock Units (RSUs), each representing a contingent right to receive one share of Common Stock, granted pursuant to the Company's Amended and Restated 2019 Incentive Plan, as amended. The RSUs vest as follows: 25% on the first day of the first month following the first anniversary of the date of grant (the Initial Vesting Date) and 25% on each anniversary of the Initial Vesting Date until fully vested. F2 · price: Each RSU was granted on May 15, 2025 for no consideration. Read SEC document |
| May 14, 2025 Filed May 15, 2025 20:29 UTC | INSMED Inc INSM · Entity 3174 | SaleCommon Stock | 1,634 | $65.61 | $107,206.74 |
DisclosureSEC source: 0001628280-25-025980 · wk-form4_1747340945.xml · nonDerivative · entry 2 Bonstein Sara · CIK 0001604019 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 108,359 F1 · kind: Shares sold to satisfy tax withholding obligations upon the vesting of Restricted Stock Units and to cover related broker fees. Read SEC document |
| May 13, 2025 Filed May 15, 2025 20:29 UTC | INSMED Inc INSM · Entity 3174 | SaleCommon Stock | 8,870 | $67.81 | $601,474.70 |
DisclosureSEC source: 0001628280-25-025980 · wk-form4_1747340945.xml · nonDerivative · entry 1 Bonstein Sara · CIK 0001604019 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 109,993 F1 · kind: Shares sold to satisfy tax withholding obligations upon the vesting of Restricted Stock Units and to cover related broker fees. Read SEC document |
| February 18, 2025 Filed Feb 20, 2025 21:52 UTC | INSMED Inc INSM · Entity 3174 | SaleCommon Stock | 700 | $81.00 | $56,700.00 |
DisclosureSEC source: 0001628280-25-006804 · wk-form4_1740088339.xml · nonDerivative · entry 2 Bonstein Sara · CIK 0001604019 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 118,863 F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F3 · price: This is the weighted average sales price representing 700 shares sold at prices ranging from $81.00 to $81.01 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. Read SEC document |
| February 18, 2025 Filed Feb 20, 2025 21:52 UTC | INSMED Inc INSM · Entity 3174 | SaleCommon Stock | 17,622 | $80.28 | $1,414,694.16 |
DisclosureSEC source: 0001628280-25-006804 · wk-form4_1740088339.xml · nonDerivative · entry 1 Bonstein Sara · CIK 0001604019 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 119,563 F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F2 · price: This is the weighted average sales price representing 17,622 shares sold at prices ranging from $80.00 to $80.99 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. Read SEC document |
| February 12, 2025 Filed Feb 13, 2025 22:09 UTC | INSMED Inc INSM · Entity 3174 | SaleCommon Stock | 5,019 | $80.00 | $401,520.00 |
DisclosureSEC source: 0001628280-25-005465 · wk-form4_1739484553.xml · nonDerivative · entry 2 Bonstein Sara · CIK 0001604019 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 137,185 F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. Read SEC document |
| February 11, 2025 Filed Feb 13, 2025 22:09 UTC | INSMED Inc INSM · Entity 3174 | SaleCommon Stock | 13,302 | $80.00 | $1,064,160.00 |
DisclosureSEC source: 0001628280-25-005465 · wk-form4_1739484553.xml · nonDerivative · entry 1 Bonstein Sara · CIK 0001604019 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 142,204 F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. Read SEC document |
| February 06, 2025 Filed Feb 7, 2025 22:10 UTC | INSMED Inc INSM · Entity 3174 | SaleCommon Stock | 28,390 | $80.90 | $2,296,751.00 |
DisclosureSEC source: 0001628280-25-004459 · wk-form4_1738966251.xml · nonDerivative · entry 2 Bonstein Sara · CIK 0001604019 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 155,506 F2 · shares: Shares sold to satisfy tax withholding obligations upon the vesting of PSUs and to cover related broker fees. F3 · price: This is the weighted average sales price representing 28,390 shares sold at prices ranging from $80.57 to $81.43 per share. The reporting person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. Read SEC document |
| February 05, 2025 Filed Feb 7, 2025 22:10 UTC | INSMED Inc INSM · Entity 3174 | GrantCommon Stock | 65,033 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-25-004459 · wk-form4_1738966251.xml · nonDerivative · entry 1 Bonstein Sara · CIK 0001604019 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 183,896 F1 · shares: Represents shares of common stock acquired upon vesting of Performance Stock Units (PSUs) that were originally granted on January 6, 2022, which vested on February 5, 2025 upon the achievement of the applicable performance and service conditions. Read SEC document |
| January 10, 2025 Filed Jan 10, 2025 23:45 UTC | INSMED Inc INSM · Entity 3174 | SaleCommon Stock | 1,066 | $63.72 | $67,925.52 |
DisclosureSEC source: 0001628280-25-001206 · wk-form4_1736552720.xml · nonDerivative · entry 4 Bonstein Sara · CIK 0001604019 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 118,863 F1 · kind: Shares sold to satisfy tax withholding obligations upon the vesting of Restricted Stock Units and to cover related broker fees. Read SEC document |
| January 08, 2025 Filed Jan 10, 2025 23:45 UTC | INSMED Inc INSM · Entity 3174 | GrantStock Option (right to buy) · Derivative | 31,930 | $0.00 Strike: $65.72 | $0.00 |
DisclosureSEC source: 0001628280-25-001206 · wk-form4_1736552720.xml · derivative · entry 5 Bonstein Sara · CIK 0001604019 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,930 Underlying: Common Stock · 31,930 shares Expires 2035-01-08 F6 · derivative.exercise_date: These stock options were granted under the Company's Amended and Restated 2019 Incentive Plan, as amended. The options become exercisable based on the following vesting schedule: 25% vest on the Initial Vesting Date and an additional 12.5% vest every six months thereafter until fully vested. Read SEC document |
| January 08, 2025 Filed Jan 10, 2025 23:45 UTC | INSMED Inc INSM · Entity 3174 | GrantCommon Stock | 6,657 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-25-001206 · wk-form4_1736552720.xml · nonDerivative · entry 3 Bonstein Sara · CIK 0001604019 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 119,929 F4 · shares: Represents Restricted Stock Units (RSUs), each representing a contingent right to receive one share of Common Stock, granted pursuant to the Company's Amended and Restated 2019 Incentive Plan, as amended. The RSUs vest as follows: 25% on the first day of the first month following the first anniversary of the date of grant (the Initial Vesting Date) and 25% on each anniversary of the Initial Vesting Date until fully vested. F5 · price: Each RSU was granted on January 8, 2025 for no consideration. Read SEC document |
| January 08, 2025 Filed Jan 10, 2025 23:45 UTC | INSMED Inc INSM · Entity 3174 | SaleCommon Stock | 1,464 | $66.05 | $96,697.20 |
DisclosureSEC source: 0001628280-25-001206 · wk-form4_1736552720.xml · nonDerivative · entry 2 Bonstein Sara · CIK 0001604019 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 113,272 F1 · kind: Shares sold to satisfy tax withholding obligations upon the vesting of Restricted Stock Units and to cover related broker fees. Read SEC document |
| January 07, 2025 Filed Jan 10, 2025 23:45 UTC | INSMED Inc INSM · Entity 3174 | SaleCommon Stock | 3,470 | $65.70 | $227,979.00 |
DisclosureSEC source: 0001628280-25-001206 · wk-form4_1736552720.xml · nonDerivative · entry 1 Bonstein Sara · CIK 0001604019 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 114,736 F1 · kind: Shares sold to satisfy tax withholding obligations upon the vesting of Restricted Stock Units and to cover related broker fees. F2 · price: This is the weighted average sales price representing 3,470 shares sold at prices ranging from $65.69 to $65.72 per share. The reporting person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. F3 · balance_after: Includes 725 shares acquired through the Company's 2018 Employee Stock Purchase Plan. Read SEC document |
| June 14, 2024 Filed Jun 17, 2024 20:30 UTC | Xilio Therapeutics, Inc. XLO · Entity 7122 | GrantStock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $1.02 | $0.00 |
DisclosureSEC source: 0001415889-24-017208 · form4-06172024_040613.xml · derivative · entry 1 Bonstein Sara · CIK 0001604019 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2034-06-13 F1 · derivative.exercise_date: The option was granted on June 14, 2024 and will vest as to 100% of the shares underlying the option on the earlier of (i) June 14, 2025 and (ii) the Issuer's next annual meeting of stockholders following the grant date, subject to the Reporting Person's continued service to the Issuer through the vesting date. Read SEC document |
| June 11, 2024 Filed Jun 13, 2024 17:00 UTC | scPharmaceuticals Inc. SCPH · Entity 74456 | GrantStock Option (Right to Buy) · Derivative | 19,750 | $0.00 Strike: $4.11 | $0.00 |
DisclosureSEC source: 0000950170-24-073117 · ownership.xml · derivative · entry 1 Bonstein Sara · CIK 0001604019 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,750 Underlying: Common Stock · 19,750 shares Expires 2034-06-11 F1 · derivative.exercise_date: This stock option vests in full upon the earlier of (i) June 11, 2025, or (ii) the next annual meeting of the Issuer's stockholders. Read SEC document |
| May 29, 2024 Filed May 30, 2024 21:41 UTC | INSMED Inc INSM · Entity 3174 | Exercise / conversionStock Option (right to buy) · Derivative | 32,156 | $0.00 Strike: $17.07 | $0.00 |
DisclosureSEC source: 0001628280-24-025886 · wk-form4_1717105276.xml · derivative · entry 26 Bonstein Sara · CIK 0001604019 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 59,350 Underlying: Common Stock · 32,156 shares Expires 2032-05-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F5 · derivative.exercise_date: The options are exercisable based on the following vesting schedule: 25% vested on the first anniversary of the grant date and an additional 12.5% vest on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant, subject to Ms. Bonstein's continued employment with the Company on each vesting date. Read SEC document |
| May 29, 2024 Filed May 30, 2024 21:41 UTC | INSMED Inc INSM · Entity 3174 | Exercise / conversionStock Option (right to buy) · Derivative | 20,111 | $0.00 Strike: $26.43 | $0.00 |
DisclosureSEC source: 0001628280-24-025886 · wk-form4_1717105276.xml · derivative · entry 24 Bonstein Sara · CIK 0001604019 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 39,275 Underlying: Common Stock · 20,111 shares Expires 2032-01-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F5 · derivative.exercise_date: The options are exercisable based on the following vesting schedule: 25% vested on the first anniversary of the grant date and an additional 12.5% vest on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant, subject to Ms. Bonstein's continued employment with the Company on each vesting date. Read SEC document |
| May 29, 2024 Filed May 30, 2024 21:41 UTC | INSMED Inc INSM · Entity 3174 | Exercise / conversionStock Option (right to buy) · Derivative | 39,446 | $0.00 Strike: $26.46 | $0.00 |
DisclosureSEC source: 0001628280-24-025886 · wk-form4_1717105276.xml · derivative · entry 22 Bonstein Sara · CIK 0001604019 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 25,740 Underlying: Common Stock · 39,446 shares Expires 2031-05-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F5 · derivative.exercise_date: The options are exercisable based on the following vesting schedule: 25% vested on the first anniversary of the grant date and an additional 12.5% vest on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant, subject to Ms. Bonstein's continued employment with the Company on each vesting date. Read SEC document |
| May 29, 2024 Filed May 30, 2024 21:41 UTC | INSMED Inc INSM · Entity 3174 | Exercise / conversionStock Option (right to buy) · Derivative | 25,046 | $0.00 Strike: $34.03 | $0.00 |
DisclosureSEC source: 0001628280-24-025886 · wk-form4_1717105276.xml · derivative · entry 20 Bonstein Sara · CIK 0001604019 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,100 Underlying: Common Stock · 25,046 shares Expires 2031-01-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F5 · derivative.exercise_date: The options are exercisable based on the following vesting schedule: 25% vested on the first anniversary of the grant date and an additional 12.5% vest on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant, subject to Ms. Bonstein's continued employment with the Company on each vesting date. Read SEC document |
| May 29, 2024 Filed May 30, 2024 21:41 UTC | INSMED Inc INSM · Entity 3174 | Exercise / conversionStock Option (right to buy) · Derivative | 27,074 | $0.00 Strike: $24.70 | $0.00 |
DisclosureSEC source: 0001628280-24-025886 · wk-form4_1717105276.xml · derivative · entry 18 Bonstein Sara · CIK 0001604019 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,362 Underlying: Common Stock · 27,074 shares Expires 2030-05-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F4 · derivative.exercise_date: The options became exercisable based on the following vesting schedule: 25% vested on the first anniversary of the grant date and an additional 12.5% vested on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant. All options are currently exercisable. Read SEC document |
| May 29, 2024 Filed May 30, 2024 21:41 UTC | INSMED Inc INSM · Entity 3174 | Exercise / conversionStock Option (right to buy) · Derivative | 76,731 | $0.00 Strike: $28.88 | $0.00 |
DisclosureSEC source: 0001628280-24-025886 · wk-form4_1717105276.xml · derivative · entry 16 Bonstein Sara · CIK 0001604019 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 11,455 Underlying: Common Stock · 76,731 shares Expires 2030-02-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F4 · derivative.exercise_date: The options became exercisable based on the following vesting schedule: 25% vested on the first anniversary of the grant date and an additional 12.5% vested on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant. All options are currently exercisable. Read SEC document |
| May 29, 2024 Filed May 30, 2024 21:41 UTC | INSMED Inc INSM · Entity 3174 | SaleCommon Stock | 220,564 | $50.00 | $11,028,200.00 |
DisclosureSEC source: 0001628280-24-025886 · wk-form4_1717105276.xml · nonDerivative · entry 14 Bonstein Sara · CIK 0001604019 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 117,481 F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F3 · price: This is the weighted average sales price representing 220,564 shares sold at prices ranging from $50.00 to $50.08 per share. The reporting person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. Read SEC document |
| May 29, 2024 Filed May 30, 2024 21:41 UTC | INSMED Inc INSM · Entity 3174 | Exercise / conversionCommon Stock | 32,156 | $17.07 | $548,902.92 |
DisclosureSEC source: 0001628280-24-025886 · wk-form4_1717105276.xml · nonDerivative · entry 12 Bonstein Sara · CIK 0001604019 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 358,769 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. Read SEC document |
| May 29, 2024 Filed May 30, 2024 21:41 UTC | INSMED Inc INSM · Entity 3174 | Exercise / conversionCommon Stock | 20,111 | $26.43 | $531,533.73 |
DisclosureSEC source: 0001628280-24-025886 · wk-form4_1717105276.xml · nonDerivative · entry 10 Bonstein Sara · CIK 0001604019 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 323,159 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. Read SEC document |
| May 29, 2024 Filed May 30, 2024 21:41 UTC | INSMED Inc INSM · Entity 3174 | Exercise / conversionCommon Stock | 39,446 | $26.46 | $1,043,741.16 |
DisclosureSEC source: 0001628280-24-025886 · wk-form4_1717105276.xml · nonDerivative · entry 8 Bonstein Sara · CIK 0001604019 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 299,594 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. Read SEC document |
| May 29, 2024 Filed May 30, 2024 21:41 UTC | INSMED Inc INSM · Entity 3174 | Exercise / conversionCommon Stock | 25,046 | $34.03 | $852,315.38 |
DisclosureSEC source: 0001628280-24-025886 · wk-form4_1717105276.xml · nonDerivative · entry 6 Bonstein Sara · CIK 0001604019 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 256,694 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. Read SEC document |
| May 29, 2024 Filed May 30, 2024 21:41 UTC | INSMED Inc INSM · Entity 3174 | Exercise / conversionCommon Stock | 27,074 | $24.70 | $668,727.80 |
DisclosureSEC source: 0001628280-24-025886 · wk-form4_1717105276.xml · nonDerivative · entry 4 Bonstein Sara · CIK 0001604019 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 228,194 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. Read SEC document |
| May 29, 2024 Filed May 30, 2024 21:41 UTC | INSMED Inc INSM · Entity 3174 | Exercise / conversionCommon Stock | 76,731 | $28.88 | $2,215,991.28 |
DisclosureSEC source: 0001628280-24-025886 · wk-form4_1717105276.xml · nonDerivative · entry 2 Bonstein Sara · CIK 0001604019 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 197,666 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. Read SEC document |
| May 28, 2024 Filed May 30, 2024 21:41 UTC | INSMED Inc INSM · Entity 3174 | Exercise / conversionStock Option (right to buy) · Derivative | 3,454 | $0.00 Strike: $17.07 | $0.00 |
DisclosureSEC source: 0001628280-24-025886 · wk-form4_1717105276.xml · derivative · entry 25 Bonstein Sara · CIK 0001604019 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 91,506 Underlying: Common Stock · 3,454 shares Expires 2032-05-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F5 · derivative.exercise_date: The options are exercisable based on the following vesting schedule: 25% vested on the first anniversary of the grant date and an additional 12.5% vest on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant, subject to Ms. Bonstein's continued employment with the Company on each vesting date. Read SEC document |
| May 28, 2024 Filed May 30, 2024 21:41 UTC | INSMED Inc INSM · Entity 3174 | Exercise / conversionStock Option (right to buy) · Derivative | 3,454 | $0.00 Strike: $26.43 | $0.00 |
DisclosureSEC source: 0001628280-24-025886 · wk-form4_1717105276.xml · derivative · entry 23 Bonstein Sara · CIK 0001604019 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 59,386 Underlying: Common Stock · 3,454 shares Expires 2032-01-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F5 · derivative.exercise_date: The options are exercisable based on the following vesting schedule: 25% vested on the first anniversary of the grant date and an additional 12.5% vest on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant, subject to Ms. Bonstein's continued employment with the Company on each vesting date. Read SEC document |
| May 28, 2024 Filed May 30, 2024 21:41 UTC | INSMED Inc INSM · Entity 3174 | Exercise / conversionStock Option (right to buy) · Derivative | 3,454 | $0.00 Strike: $26.46 | $0.00 |
DisclosureSEC source: 0001628280-24-025886 · wk-form4_1717105276.xml · derivative · entry 21 Bonstein Sara · CIK 0001604019 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 65,186 Underlying: Common Stock · 3,454 shares Expires 2031-05-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F5 · derivative.exercise_date: The options are exercisable based on the following vesting schedule: 25% vested on the first anniversary of the grant date and an additional 12.5% vest on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant, subject to Ms. Bonstein's continued employment with the Company on each vesting date. Read SEC document |
| May 28, 2024 Filed May 30, 2024 21:41 UTC | INSMED Inc INSM · Entity 3174 | Exercise / conversionStock Option (right to buy) · Derivative | 3,454 | $0.00 Strike: $34.03 | $0.00 |
DisclosureSEC source: 0001628280-24-025886 · wk-form4_1717105276.xml · derivative · entry 19 Bonstein Sara · CIK 0001604019 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 42,146 Underlying: Common Stock · 3,454 shares Expires 2031-01-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F5 · derivative.exercise_date: The options are exercisable based on the following vesting schedule: 25% vested on the first anniversary of the grant date and an additional 12.5% vest on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant, subject to Ms. Bonstein's continued employment with the Company on each vesting date. Read SEC document |
| May 28, 2024 Filed May 30, 2024 21:41 UTC | INSMED Inc INSM · Entity 3174 | Exercise / conversionStock Option (right to buy) · Derivative | 3,454 | $0.00 Strike: $24.70 | $0.00 |
DisclosureSEC source: 0001628280-24-025886 · wk-form4_1717105276.xml · derivative · entry 17 Bonstein Sara · CIK 0001604019 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 31,436 Underlying: Common Stock · 3,454 shares Expires 2030-05-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F4 · derivative.exercise_date: The options became exercisable based on the following vesting schedule: 25% vested on the first anniversary of the grant date and an additional 12.5% vested on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant. All options are currently exercisable. Read SEC document |
| May 28, 2024 Filed May 30, 2024 21:41 UTC | INSMED Inc INSM · Entity 3174 | Exercise / conversionStock Option (right to buy) · Derivative | 3,454 | $0.00 Strike: $28.88 | $0.00 |
DisclosureSEC source: 0001628280-24-025886 · wk-form4_1717105276.xml · derivative · entry 15 Bonstein Sara · CIK 0001604019 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 88,186 Underlying: Common Stock · 3,454 shares Expires 2030-02-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F4 · derivative.exercise_date: The options became exercisable based on the following vesting schedule: 25% vested on the first anniversary of the grant date and an additional 12.5% vested on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant. All options are currently exercisable. Read SEC document |
| May 28, 2024 Filed May 30, 2024 21:41 UTC | INSMED Inc INSM · Entity 3174 | SaleCommon Stock | 20,724 | $50.01 | $1,036,407.24 |
DisclosureSEC source: 0001628280-24-025886 · wk-form4_1717105276.xml · nonDerivative · entry 13 Bonstein Sara · CIK 0001604019 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 338,045 F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F2 · price: This is the weighted average sales price representing 20,724 shares sold at prices ranging from $50.00 to $50.07 per share. The reporting person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. Read SEC document |
| May 28, 2024 Filed May 30, 2024 21:41 UTC | INSMED Inc INSM · Entity 3174 | Exercise / conversionCommon Stock | 3,454 | $17.07 | $58,959.78 |
DisclosureSEC source: 0001628280-24-025886 · wk-form4_1717105276.xml · nonDerivative · entry 11 Bonstein Sara · CIK 0001604019 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 326,613 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. Read SEC document |
| May 28, 2024 Filed May 30, 2024 21:41 UTC | INSMED Inc INSM · Entity 3174 | Exercise / conversionCommon Stock | 3,454 | $26.43 | $91,289.22 |
DisclosureSEC source: 0001628280-24-025886 · wk-form4_1717105276.xml · nonDerivative · entry 9 Bonstein Sara · CIK 0001604019 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 303,048 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. Read SEC document |
| May 28, 2024 Filed May 30, 2024 21:41 UTC | INSMED Inc INSM · Entity 3174 | Exercise / conversionCommon Stock | 3,454 | $26.46 | $91,392.84 |
DisclosureSEC source: 0001628280-24-025886 · wk-form4_1717105276.xml · nonDerivative · entry 7 Bonstein Sara · CIK 0001604019 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 260,148 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. Read SEC document |
| May 28, 2024 Filed May 30, 2024 21:41 UTC | INSMED Inc INSM · Entity 3174 | Exercise / conversionCommon Stock | 3,454 | $34.03 | $117,539.62 |
DisclosureSEC source: 0001628280-24-025886 · wk-form4_1717105276.xml · nonDerivative · entry 5 Bonstein Sara · CIK 0001604019 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 231,648 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. Read SEC document |
| May 28, 2024 Filed May 30, 2024 21:41 UTC | INSMED Inc INSM · Entity 3174 | Exercise / conversionCommon Stock | 3,454 | $24.70 | $85,313.80 |
DisclosureSEC source: 0001628280-24-025886 · wk-form4_1717105276.xml · nonDerivative · entry 3 Bonstein Sara · CIK 0001604019 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 201,120 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. Read SEC document |
| May 28, 2024 Filed May 30, 2024 21:41 UTC | INSMED Inc INSM · Entity 3174 | Exercise / conversionCommon Stock | 3,454 | $28.88 | $99,751.52 |
DisclosureSEC source: 0001628280-24-025886 · wk-form4_1717105276.xml · nonDerivative · entry 1 Bonstein Sara · CIK 0001604019 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 120,935 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. Read SEC document |
| May 14, 2024 Filed May 15, 2024 20:32 UTC | INSMED Inc INSM · Entity 3174 | SaleCommon Stock | 11,088 | $25.32 | $280,748.16 |
DisclosureSEC source: 0001628280-24-023591 · wk-form4_1715805145.xml · nonDerivative · entry 2 Bonstein Sara · CIK 0001604019 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 117,481 F3 · kind: Shares sold to satisfy withholding tax obligations upon the vesting of RSUs and to cover related broker fees. F4 · price: This is the weighted average sales price representing 11,088 shares sold at prices ranging from $25.28 to $25.36 per share. The reporting person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. Read SEC document |
| May 13, 2024 Filed May 15, 2024 20:32 UTC | INSMED Inc INSM · Entity 3174 | GrantStock Option (right to buy) · Derivative | 71,160 | $0.00 Strike: $25.83 | $0.00 |
DisclosureSEC source: 0001628280-24-023591 · wk-form4_1715805145.xml · derivative · entry 3 Bonstein Sara · CIK 0001604019 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 71,160 Underlying: Common Stock · 71,160 shares Expires 2034-05-13 F5 · derivative.exercise_date: These stock options were granted under the Company's Amended and Restated 2019 Incentive Plan, as amended. The options become exercisable based on the following vesting schedule: 25% vest on the Initial Vesting Date and an additional 12.5% vest every six months thereafter through the fourth anniversary of the Initial Vesting Date. Read SEC document |
| May 13, 2024 Filed May 15, 2024 20:32 UTC | INSMED Inc INSM · Entity 3174 | GrantCommon Stock | 14,518 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-24-023591 · wk-form4_1715805145.xml · nonDerivative · entry 1 Bonstein Sara · CIK 0001604019 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 128,569 F1 · shares: Represents Restricted Stock Units (RSUs), each representing a contingent right to receive one share of Common Stock, granted pursuant to the Company's Amended and Restated 2019 Incentive Plan, as amended. The RSUs vest as follows: 25% percent on the first day of the first month following the first anniversary of the date of grant (the Initial Vesting Date) and 25% on each anniversary of the Initial Vesting Date until fully vested. F2 · price: Each RSU was granted on May 13, 2024 for no consideration. Read SEC document |
| January 09, 2024 Filed Jan 11, 2024 21:07 UTC | INSMED Inc INSM · Entity 3174 | SaleCommon Stock | 4,497 | $29.18 | $131,222.46 |
DisclosureSEC source: 0001628280-24-001160 · wk-form4_1705007232.xml · nonDerivative · entry 1 Bonstein Sara · CIK 0001604019 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 114,051 F1 · kind: Shares sold to satisfy withholding tax obligations upon the vesting of Restricted Stock Units and to cover related broker fees. F2 · price: This is the weighted average sales price representing 4,497 shares sold at prices ranging from $29.11 to $29.21 per share. The reporting person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. Read SEC document |
| January 04, 2024 Filed Jan 5, 2024 22:27 UTC | INSMED Inc INSM · Entity 3174 | GrantStock Option (right to buy) · Derivative | 63,560 | $0.00 Strike: $29.13 | $0.00 |
DisclosureSEC source: 0001628280-24-000691 · wk-form4_1704493648.xml · derivative · entry 2 Bonstein Sara · CIK 0001604019 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 63,560 Underlying: Common Stock · 63,560 shares Expires 2034-01-04 F4 · derivative.exercise_date: Stock options granted under the Company's Amended and Restated 2019 Incentive Plan. The options become exercisable based on the following vesting schedule: twenty five percent (25%) vest on the first anniversary of the grant date and an additional twelve and one half percent (12.5%) vest on each sixth month anniversary date thereafter through the fourth anniversary date of the date of grant. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.